PURPOSE: Nanocapsules composed of an oily core (Migliol 840) (MG) surrounded by a poly-epsilon-caprolactone (PECL) coat were evaluated as potential vehicles for the topical ocular administration of cyclosporin A (CyA). METHODS: A 2(3) experimental factorial design was applied to optimize the coating of the oily nanodroplets by a solvent displacement technique and to encapsulate a high dose of CyA. The variables investigated were: volume of oil (MG), amount of polymer (PECL), and volume of the organic solvent (acetone) used to dissolve the polymer. RESULTS: Nanocapsules had a mean size in the range of 210-270 nm, a negative zeta potential (between -55 and -60 mV) and a maximum loading capacity of 50% (CyA/PECL ratio). These highly loaded nanocapsules displayed a thick spongeous polymer coating around the oily nanodroplets. The corneal levels of CyA were up to 5 times higher for the encapsulated CyA than for the oily solution of CyA. In addition, these levels remained significantly higher than those of the control group (oily solution) for up to 3 days. Furthermore, the area-under-the-curve (AUC) values were significantly increased for the encapsulated CyA (319.98) with respect to the oily control (74.34). CONCLUSIONS: The CyA-loaded nanocapsules are shown to be interesting vehicles for the improvement of the ocular penetration of CyA.
PURPOSE: Nanocapsules composed of an oily core (Migliol 840) (MG) surrounded by a poly-epsilon-caprolactone (PECL) coat were evaluated as potential vehicles for the topical ocular administration of cyclosporin A (CyA). METHODS: A 2(3) experimental factorial design was applied to optimize the coating of the oily nanodroplets by a solvent displacement technique and to encapsulate a high dose of CyA. The variables investigated were: volume of oil (MG), amount of polymer (PECL), and volume of the organic solvent (acetone) used to dissolve the polymer. RESULTS: Nanocapsules had a mean size in the range of 210-270 nm, a negative zeta potential (between -55 and -60 mV) and a maximum loading capacity of 50% (CyA/PECL ratio). These highly loaded nanocapsules displayed a thick spongeous polymer coating around the oily nanodroplets. The corneal levels of CyA were up to 5 times higher for the encapsulated CyA than for the oily solution of CyA. In addition, these levels remained significantly higher than those of the control group (oily solution) for up to 3 days. Furthermore, the area-under-the-curve (AUC) values were significantly increased for the encapsulated CyA (319.98) with respect to the oily control (74.34). CONCLUSIONS: The CyA-loaded nanocapsules are shown to be interesting vehicles for the improvement of the ocular penetration of CyA.
Authors: E J Holland; T W Olsen; J M Ketcham; C Florine; J H Krachmer; J J Purcell; S Lam; H H Tessler; J Sugar Journal: Cornea Date: 1993-09 Impact factor: 2.651
Authors: Sonia Reimondez-Troitiño; Ignacio Alcalde; Noemi Csaba; Almudena Íñigo-Portugués; María de la Fuente; Federico Bech; Ana C Riestra; Jesús Merayo-Lloves; María J Alonso Journal: Drug Deliv Transl Res Date: 2016-12 Impact factor: 4.617
Authors: Baozhong Zhao; Yu-Ying He; Colin F Chignell; Jun-Jie Yin; Usha Andley; Joan E Roberts Journal: Chem Res Toxicol Date: 2009-04 Impact factor: 3.739
Authors: Joan E Roberts; Albert R Wielgus; William K Boyes; Usha Andley; Colin F Chignell Journal: Toxicol Appl Pharmacol Date: 2007-12-15 Impact factor: 4.219
Authors: Angela M de Campos; Yolanda Diebold; Edison L S Carvalho; Alejandro Sánchez; Maria José Alonso Journal: Pharm Res Date: 2004-05 Impact factor: 4.200